Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Coherus Biosciences, Inc. and Mylan, Inc.

Medical Crossfire®: Addressing Uncertainties in Oncology Biosimilars

Release Date: April 30, 2019
Expiration Date: April 30, 2020
Media: Internet - based

Activity Overview

In this Medical Crossfire® presentation, led by Dr. Francisco J. Esteva, MD, PhD, of the Perlmutter Cancer Center, panelists discuss data supporting the use of oncology biosimilars. This program covers the key regulatory aspects of biosimilars, including differences in regulatory considerations between the United States and European Union, key considerations in naming conventions, and the scientific basis for development of a biosimilar product. Case-based presentations contextualize best practices for incorporation of biosimilars into clinical practice, both as supportive care agents and, most recently, as therapeutic modalities for targeted treatment. The clinical trial basis and multidisciplinary use of these agents are also described in detail, with an emphasis on perspectives across the healthcare system, presented by clinical pharmacist Philip Coco, PharmD, BCPS, and oncology nurse practitioner Beth Faiman, PhD, APRN-BC, AOCN.

Benefits of Participation

  • Learn about the design of trials for development of therapeutic biosimilars in breast cancer, as well as supportive care agents used across cancers
  • Gain an appreciation for the variabilities that exist in origination biologic products, and the stringency of biosimilar testing to better inform patients and other healthcare professionals about the rigorous testing of these agents
  • Learn strategies for dealing with patient questions and concerns regarding biosimilars, especially regarding comparative safety and efficacy data with biosimilars and reference products
  • Know which oncology biosimilars are in development that may affect your practice in the future

CME Activity Table of Contents

  • Pretest
  • Introduction
  • Getting to Know Biosimilars in Oncology
  • A Deeper Understanding of Biosimilars
  • Case-Based Discussion
  • Medical Crossfire®: Biosimilars in Oncology
  • Integrating Biosimilars in the Cancer Treatment Paradigm: Current Approaches and Future Directions
  • Medical Crossfire®: Biosimilars in Oncology

Acknowledgement of Commercial Support

This activity is supported by educational grants from Coherus Biosciences, Inc. and Mylan, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists and nurses interested in the treatment of cancers with biosimilars.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Explain production methods, regulation, and approval of biosimilars.
  • Discuss efficacy and safety data of approved biosimilars for the treatment of cancer and how they can benefit patients.
  • Review recent clinical trials for investigational biosimilars in cancer and their potential impact on the treatment landscape.
  • Outline how to integrate biosimilars into the healthcare system based on their advantages and by educating patients in a multidisciplinary team environment.

Faculty, Staff, and Planners’ Disclosures


Francisco J. Esteva
Francisco J. Esteva, MD, PhD  
Professor, Department of Medicine
Director, Breast Medical Oncology Program
Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Grant Research Support: Genentech/Roche, Novartis, Pfizer; Consultant: Celltrion Healthcare, Genentech/Roche, Novartis.


Philip Coco
Philip Coco, PharmD, BCPS  
Clinical Pharmacy Specialist
University Medical Center of Princeton
Plainsboro, NJ

Disclosures: No relevant financial relationships with commercial interests to disclose.

Beth Faiman
Beth Faiman, PhD, APRN-BC, AOCN  
Oncology Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Disclosures: Consultant: Celgene, BMS, Takeda, Amgen; Speakers Bureau: Celgene, BMS, Takeda, Amgen.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By